All In Biotech

Drug Trial Radar · NCT07234058

Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma

A Non-Comparative Phase IIR Trial Assessing Fianlimab Plus Cemiplimab Plus Pemetrexed-Platinum Chemotherapy or Cemiplimab Plus Pemetrexed-Platinum Chemotherapy for Treatment-Naive Pleural Mesothelioma (PM) Patients

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

126

Planned (sponsor's estimate)

Start

Apr 2, 2026

Primary completion

May 2028

Study completion Sep 2029

Sponsor

Lead sponsor
Intergroupe Francophone de Cancerologie ThoraciqueAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Regeneron Pharmaceuticals
First posted
Nov 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicentre, phase IIR, double non-comparative arm trial, with an initial safety run for the anti-LAG3 arm. Approximately 40 sites will participate in the study and will enroll 126 patients with treatment-naive, unresectable malignant PM. Treatment will be administered in 21-day cycles and will continue until disease progression, unacceptable toxicity, withdrawal of consent or for 2 years immunotherapy maximum. Once the patient discontinues study treatment, the treatment period will end and the patient will enter the follow-up period. No cross-over is allowed between arms.

Conditions

  • Pleural Mesotheliomas

Interventions

  • CemiplimabDrug

    350mg every 3 weeks for up to 24 months.

  • FianlimabDrug

    1600mg every 3 weeks for up to 24 months.

  • Pemetrexed (Alimta)Drug

    500 mg/m² every 3 weeks for 6 cycles.

  • CisplatinDrug

    75 mg/m² every 3 weeks for 6 cycles.

  • Carboplatin (AUC 5)Drug

    AUC 5 (recommended maximum dose of 800 mg) every 3 weeks for 6 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the activity of the combination of double immunotherapy anti-LAG3+ anti-PD-1 and pemetrexed+platinum chemotherapyTime frame: 6 months after randomisation.

Locations

37 sites in 1 country. Site status is shown where the registry gives one.

  • Aix-Pertuis - CHI

    Aix-en-Provence, France · Not yet recruiting

  • Amiens - CHU

    Amiens, France · Not yet recruiting

  • Angers - CHU

    Angers, France · Not yet recruiting

  • Avignon - CH

    Avignon, France · Not yet recruiting

  • Besançon - CHU

    Besançon, France · Not yet recruiting

  • Bordeaux - Institut Bergonié

    Bordeaux, France · Not yet recruiting

  • Boulogne - APHP Ambroise Paré

    Boulogne-Billancourt, France · Recruiting

  • Caen - CHU

    Caen, France · Not yet recruiting

  • Clermont-Ferrand - Centre Jean Perrin

    Clermont-Ferrand, France · Not yet recruiting

  • Clermont-Ferrand - CHU

    Clermont-Ferrand, France · Not yet recruiting

  • Créteil - CHI

    Créteil, France · Not yet recruiting

  • Dijon - Centre Georges-François Leclerc

    Dijon, France · Not yet recruiting

  • Grenoble - CHU

    Grenoble, France · Not yet recruiting

  • La Roche-Sur-Yon - CHD Vendée

    La Roche-sur-Yon, France · Not yet recruiting

  • Le Mans - CHG

    Le Mans, France · Not yet recruiting

  • Lille - CHU

    Lille, France · Recruiting

  • Marseille - APHM Nord

    Marseille, France · Not yet recruiting

  • Marseille - Hôpital Européen

    Marseille, France · Not yet recruiting

  • Montpellier - CHU

    Montpellier, France · Not yet recruiting

  • Mulhouse - GHRMSA

    Mulhouse, France · Not yet recruiting

  • Nantes - Hôpital Laennec

    Nantes, France · Recruiting

  • Paris - APHP Bichat

    Paris, France · Recruiting

  • Paris - APHP Cochin

    Paris, France · Not yet recruiting

  • Bordeaux - CHU

    Pessac, France · Not yet recruiting

  • Lyon - HCL

    Pierre-Bénite, France · Not yet recruiting

  • Reims - Institut Godinot

    Reims, France · Recruiting

  • Rennes - CHU

    Rennes, France · Not yet recruiting

  • Nantes - Institut de Cancérologie de l'Ouest

    Saint-Herblain, France · Not yet recruiting

  • Saint-Nazaire - Clinique Mutualiste de l'Estuaire

    Saint-Nazaire, France · Not yet recruiting

  • Strasbourg - Nouvel Hôpital Civil

    Strasbourg, France · Recruiting

  • Toulon - CHI

    Toulon, France · Recruiting

  • Toulon - Sainte Anne HIA

    Toulon, France · Not yet recruiting

  • Toulouse - CHU

    Toulouse, France · Recruiting

  • Tours - CHU

    Tours, France · Recruiting

  • Vandoeuvre-lès-Nancy - Institut de Cancérologie de Lorraine

    Vandœuvre-lès-Nancy, France · Not yet recruiting

  • Villefranche sur Saône - CH

    Villefranche-sur-Saône, France · Not yet recruiting

  • Villejuif - Gustave Roussy

    Villejuif, France · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.